StockTipsArenaBeta

BUY Aurobindo Pharma — Arun Kumar Mantri

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byArun Kumar MantriHorizon: NA (inferred Swing (≤2wk))7 Aug 2026via CNBC Awaaz.

Entry₹1,668Inferred
Target₹1,725
Total upside +3.42% (call closed)
Stop lossNot given
At expiry₹1,621.321 Aug 2026, 3:30 pm
Expired-2.80%auction close
Follow Arun Kumar Mantri for new calls(24% target hit, 196 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 1 active Swing call on AUROPHARMASee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 21 Aug 2026
13 supporting3 neutral3 opposing
Supports the BUY call (13)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·18 Aug · 3d ago

Aurobindo Pharma Ltd has incorporated a new wholly owned subsidiary in India named 'Auropharm Overseas Limited'. The subsidiary will undertake manufacturing and marketing operations.

BSE · Company Update·13 Aug · 1w ago

(opens in new tab)

Aurobindo Pharma Expands Margins as Sales Grow

NewsGoogle News·12 Aug · 1w ago

(opens in new tab)

Results: Aurobindo Pharma Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

NewsGoogle News·8 Aug · 2w ago

(opens in new tab)

Aurobindo Pharma rises 3% after Q1 beat; HDFC Securities retains 'Add', Axis Securities cuts to 'Hold'

NewsGoogle News·7 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (3)

Aurobindo Pharma has announced its unaudited financial results for the first quarter ended June 30, 2026. The company has provided a press release detailing these results.

NSE · Press Release·5 Aug · 2w ago

(opens in new tab)

Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·5 Aug · 2w ago

(opens in new tab)

Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries

NewsCnbc-Tv18·24 Jul · 4w ago

(opens in new tab)
Weighs against the BUY call (3)

Aurobindo Pharma shares in focus after USFDA closes Raleigh unit inspection with 11 observations

NewsCnbc-Tv18·17 Aug · 4d ago

(opens in new tab)

Aurobindo Pharma shares fall after USFDA issues warning letter to Eugia's Unit 1

NewsCnbc-Tv18·14 Aug · 1w ago

(opens in new tab)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Arun Kumar Mantri

Every call and its outcome